Ruth Seggewiß-Bernhardt

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in <i>PIK3CA</i>-Altered Solid Tumors: Results From the First-in-Human Study

Dejan Juric, Jordi Rodón, Josep Tabernero et al. · Journal of Clinical Oncology · 2018 · 439 citations

Medicine, Oncology, Pharmacology +14

Alpelisib Plus Fulvestrant in <i>PIK3CA</i> -Altered and <i>PIK3CA</i> -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

Dejan Juric, Filip Jankú, Jordi Rodón et al. · JAMA Oncology · 2018 · 260 citations · Full text

Medicine, Oncology, Pharmacology +15

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

Maxim Kebenko, Marie-Elisabeth Goebeler, M. Wolf et al. · OncoImmunology · 2018 · 176 citations · Full text

Medicine, Oncology, Pharmacology +17

Pasotuxizumab, a Bite ^® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings

Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich et al. · Immunotherapy · 2020 · 144 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 1/1<scp>B</scp> trial of the heat shock protein 90 inhibitor <scp>NVP</scp>‐<scp>AUY</scp>922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma

Ruth Seggewiß-Bernhardt, Ralf C. Bargou, Yeow Tee Goh et al. · Cancer · 2015 · 72 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14